These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 24691708

  • 1. Omalizumab: stepping outside our comfort zone to broaden the number of those who can benefit.
    Cazzola M, Segreti A.
    Drugs; 2014 Apr; 74(5):535-7. PubMed ID: 24691708
    [No Abstract] [Full Text] [Related]

  • 2. How do we interpret the data supporting the use of omalizumab for severe asthma?
    Lavietes MH.
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):335-6. PubMed ID: 25256024
    [No Abstract] [Full Text] [Related]

  • 3. [Programs for continuing medical education: A session; 7. Current topics of asthma treatment--anti-IgE therapy].
    Adachi M, Tanaka A.
    Nihon Naika Gakkai Zasshi; 2012 Mar 10; 101(3):689-93. PubMed ID: 22620037
    [No Abstract] [Full Text] [Related]

  • 4. The relation of sTRAIL levels and quality of life in severe persistent allergic asthma patients using omalizumab.
    Yalcin AD, Bisgin A.
    Med Sci Monit; 2012 Aug 10; 18(8):LE9-10. PubMed ID: 22847211
    [No Abstract] [Full Text] [Related]

  • 5. Severe persistent asthma responsive to off-label use of omalizumab despite high and low levels of total serum IgE.
    Asai N, Ohkuni Y, Komatsu A, Matsunuma R, Nakashima K, Kaneko N.
    J Bras Pneumol; 2011 Aug 10; 37(4):567-70. PubMed ID: 21881749
    [No Abstract] [Full Text] [Related]

  • 6. Monitoring Allergic Patients on Omalizumab with Free and Total Serum IgE Measurements.
    Hamilton RG.
    J Allergy Clin Immunol Pract; 2016 Aug 10; 4(2):366-8. PubMed ID: 26968963
    [No Abstract] [Full Text] [Related]

  • 7. Omalizumab: a novel steroid sparing agent in eosinophilic granulomatosis with polyangiitis?
    Latorre M, Baldini C, Seccia V, Notarstefano C, Della Rossa A, Tani C, Talarico R, Mosca M, Paggiaro PL.
    Clin Exp Rheumatol; 2013 Aug 10; 31(1 Suppl 75):S91-2. PubMed ID: 23075542
    [No Abstract] [Full Text] [Related]

  • 8. Omalizumab decreases exacerbations and allows a step down in daily inhaled corticosteroid dose in adults and children with moderate-to-severe asthma.
    Thomson NC.
    Evid Based Med; 2014 Aug 10; 19(4):135. PubMed ID: 24627175
    [No Abstract] [Full Text] [Related]

  • 9. Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.
    Huffaker MF, Phipatanakul W.
    Immunol Allergy Clin North Am; 2015 Feb 10; 35(1):129-44. PubMed ID: 25459581
    [Abstract] [Full Text] [Related]

  • 10. Basophil activation test: do not lose control.
    Maietta G.
    Eur Ann Allergy Clin Immunol; 2015 Mar 10; 47(2):36-7. PubMed ID: 25781191
    [No Abstract] [Full Text] [Related]

  • 11. Against all odds: anti-IgE for intrinsic asthma?
    Lommatzsch M, Korn S, Buhl R, Virchow JC.
    Thorax; 2014 Jan 10; 69(1):94-6. PubMed ID: 23709757
    [Abstract] [Full Text] [Related]

  • 12. Anti-IgE for asthma in inner-city children.
    Geraci C, Longo G.
    N Engl J Med; 2011 Jun 30; 364(26):2557; author reply 2557-8. PubMed ID: 21714663
    [No Abstract] [Full Text] [Related]

  • 13. Omalizumab in the treatment of asthma.
    Tan R, Corren J.
    Expert Rev Respir Med; 2011 Dec 30; 5(6):747-56. PubMed ID: 22082161
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of omalizumab in severe asthma with fungal sensitisation: a case report.
    Di Stefano F, Cinti B, Antonicelli L.
    Eur Ann Allergy Clin Immunol; 2014 Jan 30; 46(1):56-9. PubMed ID: 24702879
    [Abstract] [Full Text] [Related]

  • 15. Use of omalizumab to improve desensitization safety in allergen immunotherapy.
    Larenas-Linnemann D, Wahn U, Kopp M.
    J Allergy Clin Immunol; 2014 Mar 30; 133(3):937-937.e2. PubMed ID: 24581432
    [No Abstract] [Full Text] [Related]

  • 16. Omalizumab therapy is associated with reduced circulating basophil populations in asthmatic children.
    Hill DA, Siracusa MC, Ruymann KR, Tait Wojno ED, Artis D, Spergel JM.
    Allergy; 2014 May 30; 69(5):674-7. PubMed ID: 24611974
    [Abstract] [Full Text] [Related]

  • 17. Anti-IgE for asthma in inner-city children.
    Pavord ID, Bush A.
    N Engl J Med; 2011 Jun 30; 364(26):2556-7; author reply 2557-8. PubMed ID: 21714664
    [No Abstract] [Full Text] [Related]

  • 18. [Dermatological implications of omalizumab, an anti-IgE antibody].
    Di Lucca-Chrisment J.
    Rev Med Suisse; 2015 Apr 01; 11(468):779-80, 782-3. PubMed ID: 26021140
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma.
    Tajiri T, Matsumoto H, Hiraumi H, Ikeda H, Morita K, Izuhara K, Ono J, Ohta S, Ito I, Oguma T, Nakaji H, Inoue H, Iwata T, Nagasaki T, Kanemitsu Y, Ito J, Niimi A, Mishima M.
    Ann Allergy Asthma Immunol; 2013 May 01; 110(5):387-8. PubMed ID: 23622013
    [No Abstract] [Full Text] [Related]

  • 20. Omalizumab. A review of the new treatment of allergic asthma and seasonal allergic rhinitis.
    Félix Toledo R, Negro Alvarez JM, Miralles López JC.
    Allergol Immunopathol (Madr); 2002 May 01; 30(2):94-9. PubMed ID: 11958741
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.